29/09/22 -"Dare to catch a falling knife!"
Hearing Aids stocks have been in a free-fall in the past couple of weeks. While broader MedTech sector woes had been lingering since early-2022, the sudden demise of Hearing Aids is attributed to weakening demand, supply chain woes and/or audio losing its post-pandemic outbreak lustre.
With many stocks inching closer to their 2020 lows, there’s a dilemma about whether now is the right time to dip a toe. While underlying headwinds may not dissipate soon, it’s time to go long on quality names that can clearly ‘hear and deliver’ on the market’s expectations.
AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.
|Trading in corporate shares||NO|
|Advising of corporate (strategy, marketing, debt, etc)||NO|
|Research paid for by corporate||NO|
|Provision of corporate access paid for by corporate||NO|
|Link between and a banking entity||NO|
|Brokerage activity at AlphaValue||NO|